Pàgina inicial > Resultats de la cerca: Eggermont, Alexander M.
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
11 p, 3.4 MB PIVOT-12 : a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence / Eggermont, Alexander M. (Princess Máxima Center for Pediatric Oncology & University Medical Center Utrecht) ; Ascierto, Paolo A. (Istituto Nazionale Tumori IRCCS Fondazione G Pascale) ; Khushalani, Nikhil I. (H Lee Moffitt Cancer Center & Research Institute) ; Schadendorf, Dirk (West German Cancer Center at the University Hospital Essen) ; Boland, Genevieve (Massachusetts General Hospital (Boston)) ; Weber, Jeffrey (Perlmutter Cancer Center at NYU Langone Health) ; Lewis, Karl D. (University of Colorado Cancer Center) ; Johnson, Daniel (Ochsner Medical Center) ; Rivalland, Gareth (University of Auckland & Auckland City Hospital) ; Khattak, Adnan (Hollywood Private Hospital. Edith Cowan University) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Gogas, Helen (National & Kapodistrian University of Athens) ; Long, Georgina V. (Melanoma Institute Australia. University of Sydney. Royal North Shore & Mater Hospitals) ; Currie, Sue L. (Nektar Therapeutics, San Francisco, CA 94158, USA) ; Chien, David (Nektar Therapeutics, San Francisco, CA 94158, USA) ; Tagliaferri, Mary A. (Nektar Therapeutics, San Francisco, CA 94158, USA) ; Carlino, Matteo S. (Westmead & Blacktown Hospitals & Melanoma Institute Australia. University of Sydney) ; Diab, Adi (University of Texas MD Anderson Cancer Center)
Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-1 inhibitor, has been shown to prolong survival in patients with advanced melanoma and recurrence-free survival in the adjuvant setting. [...]
2022 - 10.2217/fon-2021-1286
Future oncology (London, England), Vol. 18 Núm. 8 (january 2022) , p. 903-913  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
1 Eggermont, A.
3 Eggermont, Alexander
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem